Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma

CompletedOBSERVATIONAL
Enrollment

579

Participants

Timeline

Start Date

August 25, 2023

Primary Completion Date

July 30, 2024

Study Completion Date

July 30, 2024

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
PROCEDURE

liver resection

"This is a retrospective observational study analyzing existing clinical data; no experimental interventions were administered. The study evaluates the predictive performance of two deep learning models (preoperative and postoperative) using standard-of-care medical data collected during routine clinical practice, including:~Preoperative contrast-enhanced MRI scans Postoperative hematoxylin and eosin (H\&E)-stained whole slide images Clinical variables (laboratory results, pathology reports, and demographic data)~All data were collected as part of standard diagnostic and treatment protocols for hepatocellular carcinoma (HCC) patients undergoing liver resection. No additional interventions or modifications to clinical care were implemented for study purposes. The artificial intelligence models were applied to previously acquired, de-identified data to predict aggressive recurrence patterns"

Trial Locations (1)

430030

Tongji Hospital, Wuhan

All Listed Sponsors
collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

lead

Tongji Hospital

OTHER

NCT07030842 - Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter